相关实验视频
Updated: Jun 27, 2025

09:11
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
4.6K
葡萄糖类1受体激素使用和对糖尿病视网膜病变的影响:不确定的关系
Benjamin T K Hui1, Jian Lee Yeong1, Tunde Peto2
1Department of Ophthalmology, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Peptides
|May 5, 2024
概括
类似葡萄糖类1受体激活剂 (GLP-1RA) 提供了显著的糖尿病治疗益处,包括减肥. 然而,它们对糖尿病视网膜病变的影响仍然不确定,尽管心血管安全,但需要进一步调查.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 眼科医生 眼科 眼科
背景情况:
- 葡萄糖类1受体激动剂 (GLP-1RA) 是用于糖尿病的新型药物.
- 它们模仿天然的隐形素,增强胰岛素的释放,并提供像减肥这样的代谢益处.
- 在临床试验中,GLP-1RA已经证明了心血管安全性.
研究的目的:
- 审查GLP-1RA在糖尿病治疗中的使用.
- 探索目前对GLP-1 RA使用与糖尿病视网膜病变之间的关系的理解.
- 突出需要进一步研究GLP-1RA对糖尿病视网膜病变的影响.
主要方法:
- 对GLP-1RA的临床试验和研究的文献综述.
- 对有关糖尿病视网膜病变的心血管结局试验数据的分析.
- 确定关于糖尿病视网膜病变作为主要结果的研究缺口.
主要成果:
- GLP-1 RAs表现出强烈的抗血糖作用,并促进体重减轻.
- 已经确定GLP-1RA的心血管安全性.
- 一些试验表明GLP-1 RA使用与糖尿病视网膜病变恶化之间存在潜在联系,尽管数据有限.
结论:
- 目前GLP-1RA对糖尿病视网膜病变的影响尚不确定.
- 高血糖的快速纠正可能会导致糖尿病视网膜病变的早期恶化.
- 鉴于GLP-1RA的使用日益增加,将糖尿病视网膜病变作为主要结局的进一步试验是有必要的.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174

